the aid library

Filter

8427

Guideline on management of pneumonia and diarrhoea in children up to 10 years of age

World Health Organization WHO (2024) C_WHO

Pneumonia and diarrhoea account for 23% of under-five mortality and were responsible for an estimated 1.17 million deaths in children under five globally. Furthermore, pneumonia and diarrhoea were responsible for 18% of mortality in children 5–9 years of age, resulting in an estimated 86 000 preve ... more

Facilitator’s guide: communicating with patients about COVID-19 vaccination

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

Strategy to respond to antimalarial drug resistance in Africa

World Health Organization WHO (2022) C_WHO

The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i ... more

Eradication of yaws: a guide for programme managers

World Health Organization WHO (2018) C_WHO

This document provides guidance for countries on how to implement activities to achieve the interruption of yaws transmission. It is intended for use by national yaws eradication programmes, partners involved in the implementation of yaws eradication activities and WHO technical staff who provide te ... more

Preventing and responding to sexual misconduct WHO’s three-year strategy 2023-2025

World Health Organisation (WHO) (2023) C_WHO

Sexual exploitation, sexual abuse and sexual harassment (SEAH) violate the rights and wellbeing of the people we serve and the people with whom we serve. Such behaviours are directly in opposition to WHO’s values and our abiding responsibility to do no harm. WHO uses the umbrella term “sexual mi ... more

Lymphatic Filariasis and Podoconiosis morbidity management and disability prevention guidelines
recommended

Ministry of Health Ethiopia (2016) CC

National Guideline

Polio transition strategic framework: monitoring and evaluation

World Health Organization WHO (2024) C_WHO

The Polio Transition1 Monitoring and Evaluation (M&E) Framework was designed to monitor progress towards achieving the strategic and operational outcomes of the post-2023 Strategic Action Plan on Polio Transition (2018– 2023), as outlined in the Global Vision to use polio investments to build st ... more

Developing drinking-water quality regulations and standards: general guidance with a special focus on countries with limited resources

World Health Organization (WHO) (2018) CC

Drinking-water quality regulations and standards developed or revised in accordance with this guidance will reflect the best practices identified in the WHO Guidelines for Drinking-water Quality to most effectively protect public health. Moreover, t ... more

Water safety plan manual: step-by-step risk management for drinking-water suppliers, 2nd ed

World Health Organisation (WHO) (2023) C_WHO

Safe drinking-water management must consider drinking-water quality, acceptability and quantity in the context of public health protection. In this manual, the term “safety” encompasses these three elements. Although the principles in this manua ... more

Rapid advice : treatment of tuberculosis in children.

World Health Organization (2010) C_WHO

A practice guide to effective population-based food policy actions to promote healthy diets

World Health Organization (WHO), Regional Office for South-East Asia (2017) C_WHO

This publication provides directions for a logical, evidence informed approach to selecting, developing, implementing and monitoring population-based interventions within the context of the double-burden of malnutrition in South-East Asia. The focus of this guide is on processed or ultra-processed p ... more

Infant and young child feeding counselling: an integrated course: guidance on the use of counselling cards
recommended

World Health Organization WHO; UNICEF (2021) C_WHO

This document provides guidance to health care workers on the use of the counselling cards. The Counselling cards depict key infant and young child feeding concepts and behaviours for health workers ... more

Target product profile for a point-of-care diagnostic test for dermal leishmaniases - Control of Neglected Tropical Diseases

World Health Organization World Health Organization WHO (2022) C_WHO

Localized cutaneous leishmaniasis and its evolving forms (diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans), together with the sequela of visceral leishmaniasis (post-kala-azar dermal leishmaniasis), account for about one million cases of dermal leishmani ... more

Progress on drinking water, sanitation and hygiene in schools: 2000-2021 data update

World Health Organization WHO; UNICEF; et al. (2022) C_WHO

Special Focus on COVID-19 The report provides updated estimates for drinking water, sanitation and hygiene in schools including progress from 2015 to 2019. It highlights the rapid improvement needed to ensure students have access to handwashing facilities with soap and water during the COVID-19 pan ... more

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Model disability survey (MDS): survey manual

World Health Organization (WHO) & The World Bank (WB) WHO (2017) CC

The World Health Organization's Model Disability Survey (MDS) Manual is a tool to help implement the MDS in countries and to improve the quality of the interview process. This manual is intended to provide practical information about the survey inst ... more

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

WHO aircraft disinsection methods and procedures

World Health Organization WHO (2023) C_WHO

2nd edition. This document describes the latest methods and procedures for disinsection of internal areas of passenger, military and cargo aircraft to prevent international transport of mosquito vectors of human diseases and protect aircraft passengers and airline crew. It provides updates on insect ... more